Filing Details
- Accession Number:
- 0000899243-15-006424
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-10-07 16:12:16
- Reporting Period:
- 2015-10-05
- Filing Date:
- 2015-10-07
- Accepted Time:
- 2015-10-07 16:12:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1650504 | Lindsey Rolfe | C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-10-05 | 4,000 | $3.08 | 4,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-10-05 | 1,057 | $91.84 | 2,943 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-10-05 | 2,221 | $93.01 | 722 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-10-05 | 400 | $93.92 | 322 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-10-05 | 322 | $96.13 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Disposition | 2015-10-05 | 4,000 | $0.00 | 4,000 | $3.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,034 | 2020-04-07 | No | 4 | M | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $91.320 to $92.320 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $92.420 to $93.220 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $93.750 to $94.425 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $95.940 to $96.430 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2015.
- The option vested as to 25% of the shares on April 1, 2011, and the remainder vested in substantially equal installments over the 36 months immediately following such date.
Billionaire Hedge Funds
